The results, consistent with the lnc-ZEB2-19 overexpression, showed that the knockdown of TRA2A and RSPH14 could distinctly inhibit proliferation, migration, invasion, stemness, and resistance to lenvatinib of HCC cell lines. Here, TRA2A is linked to hepatocellular carcinoma.